September 21, Reference information: Arber DA, et al. The revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. N Engl J Med. Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
- APPLIED MATHEMATICS: MENTAL MATH MADE EASY (Fast, Quick, Rapid, Speed Vedic Arithmetic Simplified and Demystified) (Get Vedic Math by the Tail! Book 4).
- Elysian Dreams: Where the Past Meets the Present.
- Muffins Galore (Granny Maes Delights).
Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. Cancer Genome Atlas Research Network, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. Ley TJ, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Walter MJ, et al. Clonal architecture of secondary acute myeloid leukemia. Diagnosis and management of AML in adults: Eisfeld AK, et al.
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Rau R, Brown P. Nucleophosmin NPM1 mutations in adult and childhood acute myeloid leukaemia: Ho PA, et al. Lindsley RC, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Gerstung M, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Shlush LI, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. McKerrell T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Jaiswal S, et al.
Age-related clonal hematopoiesis associated with adverse outcomes.
Emerging therapies for acute myeloid leukemia: translating biology into the clinic
Busque L, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Xie M, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Steensma DP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Gibson CJ, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. Ng SW, et al. A gene stemness score for rapid determination of risk in acute leukaemia. Levis M, Small D. ITDoes matter in leukemia. The roles of FLT3 in hematopoiesis and leukemia.
Product details
Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Genomic structure of human FLT3: Molecular genetics of adult acute myeloid leukemia: Schlenk RF, et al. Identification of novel FLT-3 Asp mutations in adult acute myeloid leukaemia. Yamamoto Y, et al. Activating mutation of D within the activation loop of FLT3 in human hematologic malignancies.
Kumar R, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Auclair D, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Crump M, et al.
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: Serve H, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia SORAML: Stone RM, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation.
Yin O, et al. Levis M, et al. Muellner MK, et al. Targeting a cell state common to triple-negative breast cancers. Peter B, et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Yu J, et al. Zarrinkar PP, et al. Cortes JE, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Levis MJ, et al. Schiller GJ, et al.
- ?
- Introduction.
- Le jeu, jouer pour le plaisir et apprendre en jouant (French Edition);
- Nachhaltigkeit im Schwellenland Chile - Möglichkeiten und Hemmnisse einer Nation - Die UNO Bildungsdekade am praktischen Beispiel (German Edition).
- !
- .
- ;
- Product description?
- The Nudo Twins.
- The Slenderman: Secret Guide to Survival.
- The Orion Parallel.
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib AC in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia. Lee LY, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Ben-Batalla I, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Smith CC, et al. Heidel F, et al. Clinical resistance to the kinase inhibitor PKC in acute myeloid leukemia by mutation of Asn in the FLT3 tyrosine kinase domain. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Zimmerman EI, et al. Galanis A, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. The evolving role of FLT3 inhibitors in acute myeloid leukemia: Park IK, et al.
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Figueroa ME, et al. Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Shih AH, et al. Stein EM, et al.
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Hansen E, et al. DiNardo CD, et al. Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG, a first-in-class inhibitor of mutant IDH1. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG Clin Lymphoma Myeloma Leuk. Fathi A, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 mIDH2 J Clin Oncol.
McClintock DS, et al. Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.
2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
Nat Rev Drug Discov. Bhola PD, Letai A. Mitochondria-judges and executioners of cell death sentences. Pan R, et al. Kohl TM, et al. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Andreeff M, et al. Expression of Bclrelated genes in normal and AML progenitors: Vo TT, et al. Oltersdorf T, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Roberts AW, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Wilson WH, et al.
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: Konopleva M, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Chan SM, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Pollyea DA, et al. Okada Y, et al. Neff T, et al. Harris WJ, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.
Sriskanthadevan S, et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Cole A, et al. Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human acute myeloid leukemia. Liyanage SU, et al. Reed GA, et al. A phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Ehninger A, et al. Distribution and levels of cell surface expression of CD33 and CD in acute myeloid leukemia. Sutherland MK, et al. Anti-leukemic activity of lintuzumab SGN in preclinical models of acute myeloid leukemia.
Bross PF, et al. Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Emerging therapies for acute myeloid leukemia: translating biology into the clinic
Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Sutherland MSK, et al. A novel CDdirected antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against multi-drug resistant human AML.
Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: Kung Sutherland MS, et al. Bixby DL, et al. Vadastuximab talirine monotherapy in older patients with treatment naive CDpositive acute myeloid leukemia AML Blood. Fathi AT, et al.
Vadastuximab talirine plus hypomethylating agents: Han L, et al. Antileukemia efficacy and mechanisms of action of SL, a novel anti-CD antibody conjugate, in acute myeloid leukemia. Frankel AE, et al. Activity of SL, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Liu J, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. Teaching antibodies to engage T-cells for cancer therapy.
Curr Opin Mol Ther. Kantarjian H, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. Aigner M, et al. Laszlo GS, et al. Chichili GR, et al. Al-Hussaini M, et al. Targeting CD in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Passweg JR, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Lee DA, et al. Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: Biol Blood Marrow Transplant.
Clinical utility of natural killer cells in cancer therapy and transplantation. Shah NN, et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK J Hematother Stem Cell Res. Irradiated KHYG-1 retains cytotoxicity: Int J Radiat Biol. Lee JB, et al. Efficacy and safety of allogeneic double negative T cell as a cellular therapy for AML and its underlying mechanism.
Merims S, et al. Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Zhao Z, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Gill S, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Kenderian SS, et al. Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice.
Would you like to tell us about a lower price? This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of leukemia treatment. Leukemia treatment has undergone major change over the course of the past few years and Leukemia addresses current best practices in the light of the most recent evidence.
Read more Read less. Product description Product Description This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of leukemia treatment. Kindle Edition File Size: Demos Medical; 1 edition 29 August Sold by: Share your thoughts with other customers. Write a product review. Most helpful customer reviews on Amazon. Get to Know Us.